#United States #New York #Gross Law Firm #Sarepta Therapeutics #SRPT

Class Action Lawsuit Against Sarepta Therapeutics, Inc.

A significant legal action has unfolded as the Gross Law Firm has initiated a class action lawsuit against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) on behalf of its shareholders. This development is crucial for investors who might have suffered financial losses while holding shares of the biopharmaceutical company within a specified period.

Details of the Class Action

The class action covers shareholders who purchased shares of Sarepta Therapeutics from June 22, 2023, to June 24, 2025. Allegations detail that during this timeframe, Sarepta purportedly issued materially false statements and failed to disclose critical safety risks associated with its gene therapy product, ELEVIDYS. This gene therapy, aimed at treating Duchenne muscular dystrophy, is now at the center of scrutiny for its safety protocols and regulatory compliance.

Allegations

The lawsuit outlines several serious allegations against the company, suggesting that:
1. Safety Risks: ELEVIDYS posed significant safety threats to patients, which were not adequately communicated to investors or the public.
2. Trial Protocols: The clinical trial's methodologies failed to identify severe side effects, leading to unforeseen complications in patient health experiences.
3. Regulatory Scrutiny: These issues could force Sarepta to stop patient recruitment and dosing within its trials, attracting intensified regulatory oversight and jeopardizing the therapy's future approvals.
4. Misleading Statements: Due to the aforementioned failures, Sarepta's optimistic communications were found to be materially misleading and lacked a reasonable basis.

Deadlines and Next Steps for Shareholders

Affected shareholders are urged to act promptly, as the deadline for registering for this class action lawsuit is August 25, 2025. Interested parties can submit their information online through a designated link provided by the Gross Law Firm, ensuring they receive ongoing updates about the lawsuit's progress through a portfolio monitoring service.

It’s crucial to note that participating in this case does not require one to be a lead plaintiff, thus simplifying the process for many. This allows investors to engage in the case without incurring any financial obligations while retaining the opportunity for potential recovery.

The Role of the Gross Law Firm

The Gross Law Firm is widely recognized as a leading class action law firm, focusing on protecting investors' rights against corporate malfeasance. With a commitment to ethical business practices, the firm seeks to hold companies accountable for misleading shareholders and fostering transparency in corporate communications. They aim to recover losses incurred due to deceptive practices that artificially inflated stock prices.

Their experience equips them to manage cases effectively, ensuring that investors have the opportunity to reclaim their losses through legal avenues.

Contact Information

For more information or to begin the registration process, shareholders can reach out to the Gross Law Firm directly.

• - Address: 15 West 38th Street, 12th floor, New York, NY 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

In summary, shareholders of Sarepta Therapeutics, Inc. during the specified class period now have a chance to seek recourse. This lawsuit represents a significant step toward accountability, reflecting a broader commitment to protecting investor rights in the face of corporate negligence and misleading actions.